AbbVie (ABBV) : Wednesdays money flow points at investors jumping to buy the stock on the weakness of price. $96.61 million worth of transactions were on upticks, whereas, the downticks accounted for $55 million worth of transactions. The net money flow was a positive $41.61 million and the uptick to downtick ratio was 1.76. However, the block trades showed a clear dominance of the bulls with a very healthy ratio of 5.44 in their favor. The net money flow into the stock was $43.36 million. The value of block trades done on downticks was only $9.77 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $53.13 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. AbbVie (ABBV) was trading at $64.22, down $0.35 during day. The stock slid -0.54% over the previous days close. For the week, the stock recorded -1.17% over the previous weeks close.
Shares of AbbVie Inc. appreciated by 0.19% during the last five trading days but lost 0.45% on a 4-week basis. AbbVie Inc. is up 4.81% in the last 3-month period. Year-to-Date the stock performance stands at 11.57%.
AbbVie (ABBV) has an average broker rating of 2.27, which is interpreted as a Buy, as rated by 15 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
AbbVie (NYSE:ABBV): stock was range-bound between the intraday low of $63.885 and the intraday high of $64.94 after having opened at $64.94 on Wednesdays session. The stock finally closed in the red at $64.94, a loss of -0.54%. The stock remained in the red for the whole trading day. The total traded volume was 5,645,599 shares. The stock failed to cross $64.94 in Wednesdays trading. The stocks closing price on Thursday was $64.57.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.